Galmed Pharma to enact 1-for-12 reverse stock split

Ticker: GLMD · Form: 6-K · Filed: Aug 27, 2024 · CIK: 1595353

Galmed Pharmaceuticals LTD. 6-K Filing Summary
FieldDetail
CompanyGalmed Pharmaceuticals LTD. (GLMD)
Form Type6-K
Filed DateAug 27, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reverse-split, stock-consolidation, pharmaceuticals

TL;DR

Galmed Pharma doing a 1-for-12 reverse split on Aug 29th to boost share price.

AI Summary

Galmed Pharmaceuticals Ltd. announced on August 27, 2024, that it will implement a 1-for-12 reverse share split. This action will consolidate every twelve ordinary shares into one, with the new shares trading on August 29, 2024, after market close. The par value per share will adjust from NIS 0.15 to NIS 1.80.

Why It Matters

This reverse split is often done to increase the per-share trading price, potentially making the stock more attractive to institutional investors and meeting exchange listing requirements.

Risk Assessment

Risk Level: medium — Reverse stock splits can sometimes signal underlying financial difficulties or a lack of confidence in the company's ability to organically increase its share price.

Key Numbers

Key Players & Entities

FAQ

What is the exact date and time the reverse stock split will take effect?

The reverse share split will take effect after market close on Thursday, August 29, 2024.

What is the ratio of the reverse share split?

The ratio is 1-for-12, meaning every twelve ordinary shares will be consolidated into one ordinary share.

How does the par value of the ordinary shares change?

The par value per share will change from NIS 0.15 to NIS 1.80.

What is the purpose of this reverse stock split?

The filing does not explicitly state the purpose, but reverse splits are typically done to increase the per-share trading price.

When will the ordinary shares begin trading on a split-adjusted basis?

The filing states the shares will begin trading on the split-adjusted basis after market close on Thursday, August 29, 2024.

Filing Stats: 357 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-08-27 16:15:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: August 27, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing